← David Wainer

What podcasts say about David Wainer

Every statement, with the speaker, the exact quote and the moment it was said.

What David Wainer has said on podcasts

18 statements · 11 positive · 3 negative · 2 mixed · 2 neutral

  1. on Trump drug-pricing agreementsPositiveSep 13, 2026· WSJ's Take On the Week

    Trump’s agreements ended drug tariffs and established drug-pricing regulation.

    “Eventually, in late 2025, Trump signs these agreements, starting with Albert Bourla, the CEO of Pfizer, basically declaring the whole thing over. Tariffs are off. Drug pricing regulation is agreed upon.”

    Listen at 3:18

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  2. Large pharmaceutical companies are better at acquisitions than internal innovation.

    “They're no longer really good at innovating. They're really good at acquiring companies.”

    Listen at 4:06

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  3. on Healthcare investmentsPositiveSep 13, 2026· WSJ's Take On the Week

    Capital is rotating from AI toward healthcare investments.

    “healthcare which was kind of back here partly because of policy but also partly because ai was driving all the investment now it's sort of like money is rotating back”

    Listen at 5:28

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  4. on Personalized cancer vaccinesPositiveSep 13, 2026· WSJ's Take On the Week

    Personalized cancer vaccines target mutations identified in a patient’s tumor.

    “you're really taking the tumor and you're looking for the mutations. And then you're building a therapy based off of that to target.”

    Listen at 6:52

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  5. on ModernaPositiveSep 13, 2026· WSJ's Take On the Week

    Moderna’s market capitalization rose from about $20 billion to $50–60 billion.

    “it added over 25 to $30 billion. It was like about a $20 billion company before the announcement. It's now a 50 to $60 billion.”

    Listen at 7:23

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  6. on ModernaNegativeSep 13, 2026· WSJ's Take On the Week

    Moderna’s valuation already reflects substantial future drug revenue; investors should be cautious.

    “the market definitely is attributing like a huge future revenue to this drug. And so, you know, I'd be careful with that one.”

    Listen at 8:58

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  7. on Revolution Medicines pancreatic cancer drugPositiveSep 13, 2026· WSJ's Take On the Week

    Revolution Medicines’ approved pancreatic cancer drug extends patients’ lives.

    “this drug approved that, you know, really extends people's lives.”

    Listen at 9:31

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  8. Revolution Medicines could eventually reach a $100 billion valuation.

    “this company, which is already now about a $50 billion company, could be one of those biotechs that becomes that sort of Gilead or MJAN. that trades at $100 billion one day.”

    Listen at 10:04

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  9. Revolution Medicines will not be acquired.

    “Revolution Medicine will not get acquired.”

    Listen at 11:22

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  10. on Small biotech acquisitionsPositiveSep 13, 2026· WSJ's Take On the Week

    Large pharma should acquire smaller biotechs before their data produces major drugs.

    “go for those biotech companies that maybe in a year or two will give you that data that will become the next big drug.”

    Listen at 12:36

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  11. on biotechMixedSep 13, 2026· WSJ's Take On the Week

    Biotech is a speculative investment rather than a defensive one.

    “Biotech is more of like a speculative investment”

    Listen at 17:02

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  12. on Biotech sectorPositiveSep 13, 2026· WSJ's Take On the Week

    Biotech should continue performing while pharmaceutical M&A remains strong.

    “as long as the M&A boom, meaning pharma companies, keep buying biotech, and this year we're on pace for one of the best years ever, you're just going to keep seeing the sector work.”

    Listen at 18:04

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  13. on Novo NordiskNeutralSep 13, 2026· WSJ's Take On the Week

    Novo Nordisk’s stock is approximately back to its pre-Wegovy level.

    “If you look at Novo Nordistock, I think it's about where it was before Wiggovi came to the market”

    Listen at 18:50

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  14. on Biotech and pharmaceutical competitionNegativeSep 13, 2026· WSJ's Take On the Week

    Later entrants can displace first movers with better technology or drugs.

    “A company comes right after you, and it just has a better technology. It has a slightly better drug.”

    Listen at 19:54

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  15. Eli Lilly’s Mounjaro and Zepbound are more powerful than Novo Nordisk’s competing drugs.

    “Eli Lilly came up with this combination that just worked more powerfully. And that's what we see with Monjaro and Zeppat. And so Eli Lilly has just been eating Novo Nordisk's lunch.”

    Listen at 20:26

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  16. on KeytrudaPositiveSep 13, 2026· WSJ's Take On the Week

    Keytruda is pharma’s best-selling drug, generating over $30 billion annually.

    “the best-selling drug in pharma right now is a drug called Keytruda. It's a cancer drug. It sells over $30 billion a year”

    Listen at 25:31

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  17. on Chinese-linked Keytruda competitorPositiveSep 13, 2026· WSJ's Take On the Week

    A Chinese-linked treatment showed better cancer-patient improvement than Keytruda’s formulation alone.

    “showed better improvement to cancer patients using... the formulation that Keytruda had, but locking it in with a new target.”

    Listen at 25:54

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  18. on Chinese-linked Keytruda competitorNeutralSep 13, 2026· WSJ's Take On the Week

    The Chinese-linked cancer treatment lacks definitive overall-survival data.

    “We're still waiting for the critical thing, which is... overall survival. Did patients live longer? We're waiting for more data.”

    Listen at 26:43

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.